We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Testing Unravels Unusual Patterns for Fragile-X Syndrome

By LabMedica International staff writers
Posted on 11 Dec 2017
Print article
Image: Karyotyping of patient with Klinefelter syndrome, a chromosomal condition that affects male physical and cognitive development. Its signs and symptoms vary among affected individuals. This male has an extra X chromosome (Photo courtesy of Wellcome Trust).
Image: Karyotyping of patient with Klinefelter syndrome, a chromosomal condition that affects male physical and cognitive development. Its signs and symptoms vary among affected individuals. This male has an extra X chromosome (Photo courtesy of Wellcome Trust).
Fragile-X syndrome is an X-linked disorder with a prevalence of about 1 in 3,600 to 4,000 in males and 1 in 4,000 to 6,000 in females and is the main cause of inherited intellectual disability (ID) and cognitive impairment.

Fragile-X syndrome (FXS) is a rare disease and ID is frequently associated with chromosomal imbalances that often involve the X chromosome, and most clinicians primarily request molecular diagnosis of FXS for patients affected by any type of ID or developmental delay.

Scientists at the University of Naples Federico II (Naples, Italy) and their colleagues studied three women affected by intellectual/psychomotor delay and primary or secondary amenorrhea, and six men affected by mental retardation or psychomotor delay. The enrollees underwent FXS molecular diagnosis and resulted to have normal CGG triplets in the Fragile X Mental Retardation 1 (FMR1) gene, but showed atypical X chromosome patterns. Further diagnostic investigations and, in two females, array-comparative genomic hybridization (array-CGH) revealed the possible genetic cause of their conditions.

The team extracted DNA from 10 mL of whole blood samples from each subject and the CGG repeat number of FMR1 alleles up to 160 CGG repeats was determined by capillary gel electrophoresis of fluorescent-labeled DNA amplicons using primers F (labeled with NED fluorochrome) and C. The triplet repeat primed polymerase chain reaction (TP-PCR) and the Southern blot analysis of genomic DNA digested with restriction enzymes were performed. The X-inactivation analysis was carried out with the PCR-based method for methylation-dependent amplification of the polymorphic triplet repeats at the human androgen receptor (HUMARA) gene. Amplification products were separated by capillary gel electrophoresis on the ABI Prism 3130 genetic analyzer.

The investigators reported that six men affected by ID and three women affected by ID and fragile X-associated premature ovarian failure/ primary ovarian insufficiency (POF/POI) underwent FXS molecular testing. They had normal FMR1 CGG repeats, but atypical X chromosome patterns. Further investigations revealed that the six males had Klinefelter syndrome (XXY), one female was a Turner mosaic (X0/XX) and two women had novel rearrangements involving X chromosome.

The authors concluded that diagnostic investigation of atypical patterns at FMR1 locus can address patients and/or their relatives to further verify the condition by performing karyotyping and/or array-CGH. They emphasize that, for all the presented patients, their diagnostic report concluded for the absence of pathological expansion in the FMR1 gene and the presence of analytical findings that were suggestive of X chromosome abnormality. The study was published online on November 21, 2017, in the journal Clinica Chimica Acta.

Related Links:
University of Naples Federico II

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.